Find a Trial

Trial Summary

Protocol No.CTO-20180144
Principal InvestigatorDurm, Greg
PhasePhase I
Age GroupAdult
TitleA Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
DescriptionTo evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Life expectancy of > 3 months, in the opinion of the investigator.
  • At least 1 measurable lesion ≥ 10 mm which has not undergone biopsy within 3 months of screening scan. This lesion cannot be biopsied at any time during the study.
For a full list of participation criteria, please visit
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632